J. Maltzman

1.6k total citations · 1 hit paper
22 papers, 1.2k citations indexed

About

J. Maltzman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, J. Maltzman has authored 22 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 5 papers in Genetics. Recurrent topics in J. Maltzman's work include Advanced Breast Cancer Therapies (17 papers), HER2/EGFR in Cancer Research (16 papers) and Cancer Treatment and Pharmacology (14 papers). J. Maltzman is often cited by papers focused on Advanced Breast Cancer Therapies (17 papers), HER2/EGFR in Cancer Research (16 papers) and Cancer Treatment and Pharmacology (14 papers). J. Maltzman collaborates with scholars based in United States, United Kingdom and Peru. J. Maltzman's co-authors include Lisa O’Rourke, Stephen Johnston, Allison Florance, Mark D. Pegram, John Pippen, Xavier Pivot, Henry Gómez, Michael F. Press, Alexey Manikhas and Steven Stein and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

J. Maltzman

21 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

2009 766 citations Stephen Johnston, John Pippen et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Maltzman United States	8	1.1k	496	296	284	247	22	1.2k
Jutta Steinseifer Switzerland	10	990 0.9×	495 1.0×	212 0.7×	484 1.7×	526 2.1×	15	1.5k
Martin Olivo United States	15	1.0k 1.0×	475 1.0×	134 0.5×	270 1.0×	265 1.1×	38	1.2k
Christoph Uleer Germany	11	698 0.7×	269 0.5×	237 0.8×	296 1.0×	203 0.8×	47	917
Didier Verhoeven Belgium	16	852 0.8×	696 1.4×	86 0.3×	392 1.4×	389 1.6×	39	1.4k
Pamela Klein United States	12	770 0.7×	301 0.6×	244 0.8×	247 0.9×	469 1.9×	28	1.3k
Emanuela Ferraro United States	14	923 0.9×	399 0.8×	349 1.2×	434 1.5×	335 1.4×	54	1.3k
Karen J. Ferrante United States	9	862 0.8×	741 1.5×	100 0.3×	133 0.5×	354 1.4×	18	1.2k
Heidi Steinfeldt United States	8	586 0.6×	401 0.8×	128 0.4×	254 0.9×	694 2.8×	10	1.1k
Caroline Germa United States	16	745 0.7×	566 1.1×	112 0.4×	217 0.8×	364 1.5×	54	1.1k
Eren Demirhan United States	8	290 0.3×	678 1.4×	219 0.7×	231 0.8×	201 0.8×	15	955

Countries citing papers authored by J. Maltzman

Since Specialization

Citations

This map shows the geographic impact of J. Maltzman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Maltzman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Maltzman more than expected).

Fields of papers citing papers by J. Maltzman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Maltzman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Maltzman. The network helps show where J. Maltzman may publish in the future.

Co-authorship network of co-authors of J. Maltzman

This figure shows the co-authorship network connecting the top 25 collaborators of J. Maltzman. A scholar is included among the top collaborators of J. Maltzman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Maltzman. J. Maltzman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lipton, Allan, Kim Leitzel, Suhail M. Ali, et al.. (2011). Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression‐free survival in patients with HER2‐positive metastatic breast cancer receiving lapatinib monotherapy. Cancer. 117(21). 5013–5020. 19 indexed citations

Sherrill, Beth, Bintu Sherif, Mayur M. Amonkar, et al.. (2011). Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib. Current Medical Research and Opinion. 27(12). 2245–2252. 7 indexed citations

Schwartzberg, Lee S., Sandra Franco, Allison Florance, et al.. (2010). Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor–Positive Metastatic Breast Cancer. The Oncologist. 15(2). 122–129. 158 indexed citations

Franco, Sandra, et al.. (2010). Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor–Positive Metastatic Breast Cancer. The Oncologist. 15(3). 327–327. 13 indexed citations

Sherrill, Beth, Mayur M. Amonkar, Bintu Sherif, et al.. (2010). Quality of Life in Hormone Receptor–Positive HER-2+ Metastatic Breast Cancer Patients During Treatment with Letrozole Alone or in Combination with Lapatinib. The Oncologist. 15(9). 944–953. 24 indexed citations

Moy, Beverly, et al.. (2009). 0154 TEACH: Phase III study of lapatinib after completion of adjuvant chemotherapy in trastuzumab-naive women with HER2-positive breast cancer. The Breast. 18. S58–S58.

Blackwell, Kimberly, Mark D. Pegram, Elizabeth Tan-Chiu, et al.. (2009). Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Annals of Oncology. 20(6). 1026–1031. 136 indexed citations

Johnston, Stephen, John Pippen, Xavier Pivot, et al.. (2009). Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer. Journal of Clinical Oncology. 27(33). 5538–5546. 766 indexed citations breakdown →

Rappold, Erica, et al.. (2009). Hepatobiliary abnormalities in patients with metastatic cancer treated with lapatinib. Journal of Clinical Oncology. 27(15_suppl). 1043–1043. 25 indexed citations

10.

Lipton, Allan, et al.. (2009). Decrease in serum extracellular domain of HER2 at 4 and 8 weeks is associated with prolonged progression-free survival on lapatinib monotherapy.. Cancer Research. 69(2_Supplement). 3140–3140. 4 indexed citations

11.

Johnston, S., et al.. (2009). Correlation of tumor burden, liver and bone metastasis with serum extracellular domain HER2 expression in front-line metastatic breast cancer.. Cancer Research. 69(2_Supplement). 3146–3146. 1 indexed citations

12.

Sherif, Bintu, Beth Sherrill, Mayur M. Amonkar, et al.. (2009). Lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor positive HER2+ metastatic breast cancer (MBC): A quality-of-life (QOL) analysis. Journal of Clinical Oncology. 27(15_suppl). 1039–1039. 6 indexed citations

13.

Pivot, Xavier, J. Maltzman, Lisa O’Rourke, Allison Florance, & S. Johnston. (2009). 5077 Lapatinib plus letrozole vs. letrozole alone in patients (pts) with endocrine sensitive, HER2+, previously untreated metastatic breast cancer (MBC) with multiple (>3sites) or liver metastases. European Journal of Cancer Supplements. 7(2). 283–284. 1 indexed citations

14.

Johnston, Stephen, Mark D. Pegram, Michael F. Press, et al.. (2009). Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 Trial.. Cancer Research. 69(2_Supplement). 46–46. 49 indexed citations

15.

Maltzman, J., M. Pegram, Saeed Sadeghi, et al.. (2009). Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.. 1 indexed citations

16.

Pippen, John, Xavier Pivot, Alexey Manikhas, et al.. (2009). Safety of First-Line Letrozole Compared with Lapatinib Plus Letrozole in Patients with Postmenopausal Hormone Receptor Positive Metastatic Breast Cancer: EGF30008 Study.. Cancer Research. 69(24_Supplement). 5094–5094. 4 indexed citations

17.

Koehler, Martin Johannes, Lisa O’Rourke, J. Maltzman, et al.. (2009). Relevance of serum HER2 extracellular domain (sECD) in EGF30008, a study of letrozole ± lapatinib in patients (pts) with hormone-receptor positive (HR+) metastatic breast cancer (MBC). Journal of Clinical Oncology. 27(15_suppl). 1019–1019. 2 indexed citations

18.

Sherrill, Beth, Mayur M. Amonkar, Bintu Sherif, et al.. (2009). An Exploration of the Association of Quality-of-Life (QOL) Scores with Tumor Progression Status in First Line Hormone Receptor Positive, HER2+ Metastatic Breast Cancer (MBC) Patients Treated with Lapatinib Plus Letrozole or Letrozole Alone.. Cancer Research. 69(24_Supplement). 5106–5106. 4 indexed citations

19.

Sherrill, Beth, Mayur M. Amonkar, Bintu Sherif, et al.. (2009). 5048 A Q-TWiST analysis of lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor positive (HR+) metastatic breast cancer (MBC). European Journal of Cancer Supplements. 7(2). 275–275. 2 indexed citations

20.

Moy, Beverly, J. Maltzman, & Paul E. Goss. (2007). P119 Phase III study of lapatinib after completion of adjuvant chemotherapy in trastuzumab-naive women with ErbB2-overexpressing breast cancer: Tykerb evaluation after chemotherapy (TEACH) study. The Breast. 16. S47–S47. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact